vs
Meridian Corp（MRBK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Meridian Corp的季度营收约是REGENXBIO Inc.的1.1倍（$34.2M vs $30.3M），Meridian Corp净利率更高（428.0% vs -221.3%，领先649.3%），REGENXBIO Inc.同比增速更快（43.0% vs 5.1%），Meridian Corp自由现金流更多（$22.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 18.0%）
英国子午线音响是一家消费音响与家庭影院设备制造商，由鲍勃·斯图尔特与艾伦·布思罗伊德于1977年创立，最初名为Boothroyd-Stuart。1985年该公司推出了首款以Meridian为品牌的CD播放器，1998年研发了无损压缩格式Meridian Lossless Packing，2014年推出了Master Quality Authenticated认证有损音频格式MQA。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MRBK vs RGNX — 直观对比
营收规模更大
MRBK
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出37.9%
5.1%
净利率更高
MRBK
高出649.3%
-221.3%
自由现金流更多
MRBK
多$75.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
18.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $30.3M |
| 净利润 | $7.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 27.2% | -190.0% |
| 净利率 | 428.0% | -221.3% |
| 营收同比 | 5.1% | 43.0% |
| 净利润同比 | 28.3% | -31.2% |
| 每股收益（稀释后） | $0.61 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRBKRGNX
| Q4 25 | $34.2M | $30.3M | ||
| Q3 25 | $33.1M | $29.7M | ||
| Q2 25 | $32.4M | $21.4M | ||
| Q1 25 | $27.1M | $89.0M | ||
| Q4 24 | $32.6M | $21.2M | ||
| Q3 24 | $29.1M | $24.2M | ||
| Q2 24 | $26.1M | $22.3M | ||
| Q1 24 | $24.6M | $15.6M |
净利润MRBKRGNX
| Q4 25 | $7.2M | $-67.1M | ||
| Q3 25 | $6.7M | $-61.9M | ||
| Q2 25 | $5.6M | $-70.9M | ||
| Q1 25 | $2.4M | $6.1M | ||
| Q4 24 | $5.6M | $-51.2M | ||
| Q3 24 | $4.7M | $-59.6M | ||
| Q2 24 | $3.3M | $-53.0M | ||
| Q1 24 | $2.7M | $-63.3M |
毛利率MRBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率MRBKRGNX
| Q4 25 | 27.2% | -190.0% | ||
| Q3 25 | 26.2% | -176.3% | ||
| Q2 25 | 22.5% | -296.3% | ||
| Q1 25 | 11.6% | 13.6% | ||
| Q4 24 | 23.3% | -242.1% | ||
| Q3 24 | 21.5% | -256.6% | ||
| Q2 24 | 16.8% | -251.3% | ||
| Q1 24 | 14.4% | -408.8% |
净利率MRBKRGNX
| Q4 25 | 428.0% | -221.3% | ||
| Q3 25 | 20.1% | -208.3% | ||
| Q2 25 | 17.2% | -331.8% | ||
| Q1 25 | 8.9% | 6.8% | ||
| Q4 24 | 366.8% | -241.3% | ||
| Q3 24 | 16.3% | -246.3% | ||
| Q2 24 | 12.7% | -237.7% | ||
| Q1 24 | 10.9% | -405.4% |
每股收益（稀释后）MRBKRGNX
| Q4 25 | $0.61 | $-1.30 | ||
| Q3 25 | $0.58 | $-1.20 | ||
| Q2 25 | $0.49 | $-1.38 | ||
| Q1 25 | $0.21 | $0.12 | ||
| Q4 24 | $0.49 | $-0.99 | ||
| Q3 24 | $0.42 | $-1.17 | ||
| Q2 24 | $0.30 | $-1.05 | ||
| Q1 24 | $0.24 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $199.7M | $102.7M |
| 总资产 | $2.6B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MRBKRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益MRBKRGNX
| Q4 25 | $199.7M | $102.7M | ||
| Q3 25 | $188.0M | $161.5M | ||
| Q2 25 | $178.0M | $213.7M | ||
| Q1 25 | $173.6M | $274.2M | ||
| Q4 24 | $171.5M | $259.7M | ||
| Q3 24 | $167.4M | $301.4M | ||
| Q2 24 | $162.4M | $348.3M | ||
| Q1 24 | $159.9M | $390.7M |
总资产MRBKRGNX
| Q4 25 | $2.6B | $453.0M | ||
| Q3 25 | $2.5B | $525.2M | ||
| Q2 25 | $2.5B | $581.0M | ||
| Q1 25 | $2.5B | $490.9M | ||
| Q4 24 | $2.4B | $466.0M | ||
| Q3 24 | $2.4B | $519.1M | ||
| Q2 24 | $2.4B | $569.4M | ||
| Q1 24 | $2.3B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $24.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $22.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 65.9% | -174.0% |
| 资本支出强度资本支出/营收 | 5.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.38× | — |
| 过去12个月自由现金流最近4个季度 | $51.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MRBKRGNX
| Q4 25 | $24.3M | $-52.3M | ||
| Q3 25 | $24.4M | $-56.0M | ||
| Q2 25 | $-12.0M | $-49.3M | ||
| Q1 25 | $18.1M | $33.6M | ||
| Q4 24 | $9.6M | $-31.6M | ||
| Q3 24 | $31.2M | $-40.5M | ||
| Q2 24 | $-19.2M | $-45.5M | ||
| Q1 24 | $-1.7M | $-55.5M |
自由现金流MRBKRGNX
| Q4 25 | $22.6M | $-52.8M | ||
| Q3 25 | $24.0M | $-56.5M | ||
| Q2 25 | $-12.7M | $-49.7M | ||
| Q1 25 | $17.9M | $32.6M | ||
| Q4 24 | $9.0M | $-32.7M | ||
| Q3 24 | $29.5M | $-40.9M | ||
| Q2 24 | $-19.3M | $-46.0M | ||
| Q1 24 | $-3.6M | $-56.0M |
自由现金流率MRBKRGNX
| Q4 25 | 65.9% | -174.0% | ||
| Q3 25 | 72.4% | -189.9% | ||
| Q2 25 | -39.1% | -232.8% | ||
| Q1 25 | 65.9% | 36.6% | ||
| Q4 24 | 27.7% | -154.2% | ||
| Q3 24 | 101.4% | -168.9% | ||
| Q2 24 | -73.8% | -206.2% | ||
| Q1 24 | -14.7% | -358.5% |
资本支出强度MRBKRGNX
| Q4 25 | 5.1% | 1.7% | ||
| Q3 25 | 1.4% | 1.7% | ||
| Q2 25 | 1.9% | 1.8% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | 1.7% | 5.1% | ||
| Q3 24 | 6.0% | 1.3% | ||
| Q2 24 | 0.2% | 2.1% | ||
| Q1 24 | 7.8% | 3.6% |
现金转化率MRBKRGNX
| Q4 25 | 3.38× | — | ||
| Q3 25 | 3.66× | — | ||
| Q2 25 | -2.15× | — | ||
| Q1 25 | 7.55× | 5.53× | ||
| Q4 24 | 1.71× | — | ||
| Q3 24 | 6.58× | — | ||
| Q2 24 | -5.78× | — | ||
| Q1 24 | -0.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRBK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
